Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million
Bitget2026/09/24 15:40- Eurobio Scientific first-half revenue rose 4.5% to €84.5 million, while operating income climbed 45% to €8.5 million.
- Net income more than doubled to €4.7 million; EBITDA increased 20% to €15.8 million.
- Gross margin rate edged up 0.2 percentage points to 47.5%, and operating expenses fell to 35.1% of revenue from 37.2%.
- Free cash flow totaled €4 million, and net debt stood at €147.4 million, including the EB Development shareholder loan.
- CareDx’s Lab Solutions acquisition closed June 30, and EB Development proposed a tender offer at €25.30 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
